Enteropathy-associated T-cell lymphoma
MONDO:0019473An uncommon mature T-cell lymphoma of intraepithelial lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum. Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is seen with increased frequency in regions with a high prevalence of celiac disease.
Also known as: EATL, EATL, type I, ETTL, enteropathy associated T-cell lymphoma, enteropathy-associated T-cell lymphoma, type I, enteropathy-type T-cell lymphoma, intestinal T-cell lymphoma, EATCL
1947 clinical trials for this condition and its sub-types, 20 tagged with Enteropathy-associated T-cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Enteropathy-associated T-cell lymphoma
-
New combo shows promise against Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of the targeted drug brentuximab vedotin (ADCETRIS) plus standard CHP chemotherapy in 82 people with newly diagnosed peripheral T-cell lymphoma (PTCL) that has low CD30 levels. The goal was to see how many patients' tumors shrank or disappeared. Re…
Phase 2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail aims to tackle rare blood cancer
Disease control CompletedThis phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemother…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study tested a drug called brentuximab vedotin in 23 people with a type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, even when levels of…
Phase 2 • Sponsor: Deepa Jagadeesh • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC